Press Releases GSK plc Nyse

Equities

GSK

US37733W2044

Market Closed - Nyse Other stock markets 21:00:02 15/05/2024 BST			5-day change	1st Jan Change
45.7 ^USD	+0.09%		+3.53%	+23.31%

05-15	Abu Dhabi to Host GSK's Regional Vaccine Hub Under New Health Partnership	MT
05-14	GSK: towards the creation of a vaccine center in Abu Dhabi	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GSK : to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR)	12:04am	PU
GSK : Director/Pdmr Shareholding - Form 6-K	05-14	PU
GSK : BLOCK LISTING SIX MONTHLY RETURN - Form 6-K	05-13	PU
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million	05-07	AQ
GSK : Q1 2024 results transcript	05-02	PU
GSK : Q1 2024 results slides	05-02	PU
GSK : Q1 2024 results infographic	05-02	PU
Glaxo: Q1 Earnings Snapshot	05-01	AQ
US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer \| GSK	04-24	AQ
GSK : Director/Pdmr Shareholding - Form 6-K	04-19	PU
EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments \| GSK	04-17	AQ
New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade \| GSK	04-17	AQ
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments - Form 6-K	04-17	PU
GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA \| GSK	04-17	AQ
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments	04-17	PU
GSK : New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade	04-17	PU
GSK : 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA - Form 6-K	04-16	PU
GSK : 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA	04-16	PU
GSK : Q1 2024 pre announcement aide memoire	04-11	PU
WuXi Biologics Reports Solid 2023 Annual Results	03-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK plc : Back on track

May 03, 2024 at 10:17 am

GSK PLC : Encouraging start to 2024; guidance raised

May 01, 2024 at 04:38 pm